Could BTK degraders outperform pirtobrutinib against BTK resistance mutations in CLL?

Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses the potential of BTK degraders, such as tacabrutideg and bexobrutideg, to treat chronic lymphocytic leukemia (CLL), highlighting their ability to target multiple BTK mutations. Prof. Danilov believes these degraders may play a role in earlier lines of therapy, and notes that they have shown effectiveness against a range of mutations that pirtobrutinib does not address. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.